Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501922 | 1.00 | CDK1 (0.51) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL29501824 | 0.87 | CDK1 (0.53) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL449338 | 0.87 | CDK1 (0.53) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL3059627 | 0.82 | CDK1 (0.74) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL461976 | 0.81 | CDK1 (0.56) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL448405 | 0.80 | CDK1 (0.74) | CDK1CCNE2CCNE1CDK2PPARG | |
| SCHEMBL29501930 | 0.79 | CDK1 (0.57) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL450530 | 0.79 | CDK1 (0.57) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL450636 | 0.79 | CDK1 (0.54) | CDK1KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL447252 | 0.79 | ADORA3 (0.59) | CDK1KDM4ECCNB2CCNE2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | claimed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2020-09-22 | — | — | US | disclosed |
| WO-2020141535-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2020-07-09 | — | — | WO | disclosed |
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| EP-1959939-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | Can-Fite Biopharma Ltd. (IL) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007063538-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| US-20070099865-A1 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099865-A1 | Treatment of dry eye conditions | ADORA3, ADORA2A, ADORA2B | CDK1 4171/4885KDM4E 2513/4885CCNB2 3891/4885 |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | CDK1 4761/4885KDM4E 3381/4885CCNB2 3477/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | CDK1 1237/4885KDM4E 3373/4885CCNB2 1798/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | CDK1 4077/4885KDM4E 4799/4885CCNB2 4744/4885 |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | CDK1 4203/4885KDM4E 2460/4885CCNB2 3929/4885 |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | GPR119, FABP1, INSR | CDK1 4661/4885KDM4E 3609/4885CCNB2 1961/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | CDK1 1825/4885KDM4E 3633/4885CCNB2 2278/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | CDK1 1240/4885KDM4E 4771/4885CCNB2 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.